|
|
|
|
Ulcerative colitis: Natural historyan optimistic message from Norway
_ Ulcerative colitis: Natural historyan optimistic message from Norway.
Nature Clinical Practice Gastroenterology & Hepato:
Jul 3 2009 10:28AM
Matching: ulcerative
|
Find similar documents
|
|
|
|
Contest Offers Young Hockey Enthusiasts the Chance to Play with Fernando Pisani of the Edmonton Oilers
TORONTO, June 29 /CNW/ - This August, children across Canada between the ages of 10 and 12, will have a chance to give back to their communities while lacing up their skates during the Score for Colitis and Crohn's national contest...
|
|
|
Risk factors for colorectal cancer
In Robeson County, there is an average of 21 deaths per year because of colon and rectal cancer.No one knows the exact causes of colorectal cancer. Doctors often cannot explain why one person develops this disease and another does not....
|
|
|
Pharming gets Dutch govt grant to develop human lactoferrin for IBD
Biotech company Pharming Group NV (Pharming) has initiated a two-year Food & Nutrition Delta (FND) innovation project to further develop human lactoferrin (hLF) as a nutritional product to manage inflammatory bowel diseases (IBD).The...
|
|
|
Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal
Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved...
|
|
|
Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawal
June 2009: Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who...
|
|
|
Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI) BioMed Conference
There is a keen interest in the field of cellular therapy, particularly in the niche of cell therapy where matching between the donor and the patient is not required, stated Mr.Aberman. The placenta is a great source for cell therapy,...
|
|
|
Ulcerative colitis: Appendicitis, but not appendectomy, reduces risk of ulcerative colitis
_ Ulcerative colitis: Appendicitis, but not appendectomy, reduces risk of ulcerative colitis.
Nature Clinical Practice Gastroenterology & Hepato:
Jun 4 2009 9:37AM
Matching: ulcerative
|
Find similar documents
|
|
|
|
Inflammatory bowel disease on the rise in specific populations
Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several...
|
|
|
Greater Incidence Of Inflammatory Bowel Disease In Specific Populations
Health outcomes explored at DDW 2009 Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half...
|
|
|
Shire Presented Results Of A New Database Analysis On Lialda(R) (Mesalamine) And Other 5-ASAs For Ulcerative C
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, 'Twelve-month Persistence with 5-aminosalicylic Acid Therapy:...
|
|
|
Inflammatory bowel disease on the rise in specific populations
Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several...
|
|
|
Inflammatory bowel disease on the rise in specific populations
Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several...
|
|
|
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative C
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, 'Twelve-month Persistence...
|
|
|
Corrigendum: Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
Mark S Silverberg Judy H Cho John D Rioux Dermot P B McGovern Jing Wu Vito Annese Jean-Paul Achkar Philippe Goyette Regan Scott Wei Xu M Michael Barmada Lambertus Klei Mark J Daly Clara Abraham Theodore M Bayless Fabrizio Bossa Anne M...
|
|
|
Pluristem Therapeutics to Present at the International Society for Stem Cell Research (ISSCR) 7th Annual Meeti
We at Pluristem, are thrilled to be part of the prestigious ISSCR conference, where the finest of stem cell researchers present, stated Zami Aberman, Chairman, President and CEO of Pluristem.I believe that innovative research done at...
|
|
|
Sanofi-aventis gets worldwide rights to Kyowa Hakko Kirin's anti-light human monoclonal antibody
Sanofi-aventis and Kyowa Hakko Kirin Co, Ltd (Kyowa Hakko Kirin) signed a collaboration and licensing agreement under which sanofi-aventis receives worldwide rights to Kyowa Hakko Kirin's Anti-Light fully human monoclonal antibody.This...
|
|
|
Pluristem Therapeutics to Present at the 2009 BIO International Convention as Part of the Israeli Delegation
The life science industry in general and cell therapy in particular is an exciting field for scientists, physicians and investors, stated Zami Aberman, Chairman, President and CEO of Pluristem.The BIO International Convention is the...
|
|
|
'Speed of Relief' a Key Factor in Selecting Ulcerative Colitis Treatment: New Study
Canadian ulcerative colitis patients and gastroenterologists say speed to symptom relief and few side effects are the most important factors in choosing treatment options TORONTO, May 4 /CNW/ - A Canadian study examining patient needs in the...
|
|
|
For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the In
Abbott/Eisai's Humira Will Earn Decision Resources' Clinical Gold Standard Status for Ulcerative Colitis in 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 16 /PRNewswire/ -- Decision Resources, one...
|
